Márk Barok

2.1k total citations · 1 hit paper
22 papers, 1.6k citations indexed

About

Márk Barok is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Márk Barok has authored 22 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Molecular Biology. Recurrent topics in Márk Barok's work include Monoclonal and Polyclonal Antibodies Research (17 papers), HER2/EGFR in Cancer Research (16 papers) and Cell Adhesion Molecules Research (6 papers). Márk Barok is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (17 papers), HER2/EGFR in Cancer Research (16 papers) and Cell Adhesion Molecules Research (6 papers). Márk Barok collaborates with scholars based in Finland, Hungary and Canada. Márk Barok's co-authors include Jorma Isola, Heikki Joensuu, Minna Tanner, János Szöllõsi, György Vereb, Péter Nagy, Maija Puhka, István Juhász, Vadim Le Joncour and Markku Tammi and has published in prestigious journals such as Cancer Research, International Journal of Cancer and European Journal of Cancer.

In The Last Decade

Márk Barok

20 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab emtansine: mechanisms of action and drug resistance

2014 426 citations Márk Barok, Heikki Joensuu et al. Breast Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Márk Barok Finland	15	1.2k	838	597	246	184	22	1.6k
Elaine Mai United States	13	1.7k 1.4×	1.5k 1.8×	809 1.4×	260 1.1×	89 0.5×	20	2.3k
Lisa Crocker United States	13	2.1k 1.7×	1.6k 1.9×	959 1.6×	454 1.8×	205 1.1×	25	2.7k
Natalia Sergina United States	9	866 0.7×	489 0.6×	681 1.1×	252 1.0×	113 0.6×	9	1.3k
Kathryn L. Parsons United States	6	2.1k 1.7×	1.8k 2.2×	958 1.6×	314 1.3×	135 0.7×	11	2.7k
Kim Leitzel United States	20	1.3k 1.0×	743 0.9×	623 1.0×	219 0.9×	330 1.8×	35	1.6k
Kendall D. Carey United States	10	1.1k 0.9×	651 0.8×	951 1.6×	373 1.5×	121 0.7×	12	1.9k
Xenia Jimenez United States	22	670 0.5×	630 0.8×	1.2k 2.0×	227 0.9×	280 1.5×	27	1.7k
Eveline Trachsel Switzerland	23	716 0.6×	929 1.1×	623 1.0×	148 0.6×	163 0.9×	29	1.7k
Kim Pedersen Spain	12	761 0.6×	449 0.5×	351 0.6×	112 0.5×	139 0.8×	14	992
Thinh Q. Pham United States	8	913 0.7×	411 0.5×	629 1.1×	303 1.2×	183 1.0×	10	1.3k

Countries citing papers authored by Márk Barok

Since Specialization

Citations

This map shows the geographic impact of Márk Barok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Márk Barok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Márk Barok more than expected).

Fields of papers citing papers by Márk Barok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Márk Barok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Márk Barok. The network helps show where Márk Barok may publish in the future.

Co-authorship network of co-authors of Márk Barok

This figure shows the co-authorship network connecting the top 25 collaborators of Márk Barok. A scholar is included among the top collaborators of Márk Barok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Márk Barok. Márk Barok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Joncour, Vadim Le, György Vereb, Jorma Isola, et al.. (2025). Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan. Translational Oncology. 53. 102284–102284. 1 indexed citations

Barok, Márk, Heikki Joensuu, Natalie Zeytuni, et al.. (2025). Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering. Biomolecules. 15(5). 606–606.

Katainen, Riku, Jun Dai, Anna Vähärautio, et al.. (2025). Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates. Cancer Letters. 630. 217900–217900. 2 indexed citations

Joncour, Vadim Le, et al.. (2024). Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model. Clinical & Experimental Metastasis. 41(2). 91–102. 11 indexed citations

Attalla, Sherif Samer, Jonathan Boucher, Tarek Taifour, et al.. (2023). HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer. Cancer Immunology Research. 11(9). 1184–1202. 7 indexed citations

Barok, Márk, et al.. (2020). ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Cancer Letters. 473. 156–163. 64 indexed citations

Joncour, Vadim Le, Maija Puhka, Jorma Isola, et al.. (2019). A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. Molecular Cancer Therapeutics. 18(10). 1721–1730. 71 indexed citations

Barok, Márk, Maija Puhka, György Vereb, et al.. (2018). Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. BMC Cancer. 18(1). 504–504. 71 indexed citations

Staff, Synnöve, et al.. (2016). Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer. Applied immunohistochemistry & molecular morphology. 26(3). 212–219. 4 indexed citations

10.

Barok, Márk, Heikki Joensuu, & Jorma Isola. (2014). Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Research. 16(2). 209–209. 426 indexed citations breakdown →

11.

Barok, Márk, et al.. (2011). Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Letters. 306(2). 171–179. 124 indexed citations

12.

Barok, Márk, et al.. (2011). Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Research. 13(2). R46–R46. 173 indexed citations

13.

Barok, Márk, Minna Tanner, Synnöve Staff, et al.. (2010). Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Letters. 294(2). 211–219. 90 indexed citations

14.

Friedländer, Elza, Márk Barok, János Szöllõsi, & György Vereb. (2008). ErbB-directed immunotherapy: Antibodies in current practice and promising new agents. Immunology Letters. 116(2). 126–140. 53 indexed citations

15.

Fábián, Ákos, Márk Barok, György Vereb, & János Szöllõsi. (2008). Die hard: Are cancer stem cells the Bruce Willises of tumor biology?. Cytometry Part A. 75A(1). 67–74. 70 indexed citations

16.

Barok, Márk, Tamás Kovács, Hideyuki Saya, et al.. (2008). EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. Cancer Letters. 263(2). 231–242. 30 indexed citations

17.

Barok, Márk, et al.. (2007). Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. European Journal of Cancer. 43(16). 2423–2433. 117 indexed citations

18.

Rákosy, Zsuzsa, Laura Vízkeleti, Szilvia Ecsedi, et al.. (2007). EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. International Journal of Cancer. 121(8). 1729–1737. 70 indexed citations

19.

Barok, Márk, Margit Balázs, Péter Nagy, et al.. (2007). Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Letters. 260(1-2). 198–208. 38 indexed citations

20.

Barok, Márk, Jorma Isola, Péter Nagy, et al.. (2007). Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Molecular Cancer Therapeutics. 6(7). 2065–2072. 180 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact